Se încarcă compania
Just reported
Q3 2026 results
From Amgen's results release of 3 noiembrie 2026; its quarterly report has since been filed.
Revenue
Actual
10,37B USD
+8,5 % y/y
+3,1 % q/qGuided
—
No guide given
EPS, GAAP
Actual
7,08 USD
+19 % y/y
+62 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
3,71B USD
+47 % y/y
+5,6 % q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue38,9B USD – 39,7B USD+6,9 % y/y Raised +1,3 %
- EPS, adjusted22,90 USD – 23,70 USDRaised +1,7 %
- EPS, GAAP18,34 USD – 19,28 USD+32 % y/y Raised +14 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Amgen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,35T USDA+
JNJJohnson & Johnson682,6B USDA+
MRKMerck & Co., Inc.362,2B USDA
NVSNovartis AG305,8B USDA
GILDGilead Sciences, Inc.208,3B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Cum face bani
- Repatha prescription sales9 %
- Otezla prescription sales7 %
- Enbrel prescription sales7 %
- EVENITY prescription sales7 %
- XGEVA prescription sales6 %
- TEPEZZA prescription sales6 %
Ponderile din venituri sunt estimări pentru year ended 2025-12-31, high confidence, nu cifre dintr-un raport depus.
Concurează cu
Ce vinde6
Repatha
An injectable medicine that lowers LDL cholesterol and is used to reduce the chance of major heart and blood-vessel events in certain adults.
Prolia
A medicine for osteoporosis that helps reduce fracture risk in certain people, including postmenopausal women and men at high risk of fracture.
Otezla
An oral medicine used for plaque psoriasis, psoriatic arthritis and certain mouth ulcers.
Afișează încă 3
ENBREL
A medicine used for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
TEZSPIRE
An antibody medicine used as an add-on treatment for severe uncontrolled asthma and, in approved markets, chronic sinus inflammation with nasal polyps.
IMDELLTRA
A cancer medicine for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.
Cine cumpără3
- In the United States, Amgen sells substantially all its products to pharmaceutical wholesalers, which then distribute them to healthcare providers. McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
- Outside the United States, Amgen sells to healthcare providers and pharmaceutical wholesalers, depending on local distribution practices.
- Healthcare providers, including physicians and their clinics, hospitals, dialysis centers and pharmacies, use or dispense Amgen medicines; some products are also marketed through direct-to-patient channels.
Pe ce se sprijină și ce l-ar putea dărâma
De ce depinde activitatea
- 1Amgen relies on large wholesalers for distribution: McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
- 2The United States is its largest market, accounting for 71.9% of revenue by geography (year ended 2025-12-31, high confidence).
- 3Its sales depend on government and commercial insurers covering its medicines and deciding how much they will reimburse; coverage rules and required discounts can affect use and net prices.
- 4The 10-K says a substantial majority of commercial manufacturing takes place in Puerto Rico and a substantial majority of clinical manufacturing takes place in Thousand Oaks, California.
- 5Amgen relies on third-party suppliers for some raw materials, devices and components, including items for which a supplier may be its only source.
Ce ar putea merge prost
- 1Government and private payer policies can limit access or reduce the prices Amgen receives. The filings describe Medicare price setting for ENBREL and Otezla, expanded discounts through the 340B program, and other pricing policies as pressures on sales and profitability.
- 2Biosimilar and generic competition can reduce sales and prices. The patents for Prolia and XGEVA have expired in key markets, and the 10-Q reports lower sales as biosimilar competitors entered those markets.
- 3Manufacturing disruption could limit medicine supply and sales. The 10-K identifies concentration of commercial manufacturing in Puerto Rico and clinical manufacturing in Thousand Oaks, California, as potential sources of disruption.
Situațiile financiare complete →
Despre Amgen Inc.
Amgen researches, develops and manufactures medicines, including biologic medicines made using living cells and small-molecule drugs. It sells treatments for conditions including heart disease, cancer, osteoporosis, asthma and autoimmune diseases. It also sells biosimilar medicines, which are highly similar versions of existing biologic medicines.
- Sediu
- Thousand Oaks, California
- Înființată în
- 1980 (incorporated in California; high confidence)
- Listată la
- NASDAQ
- Sfârșitul exercițiului financiar
- December 31
Construit din raportările proprii ale Amgen Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
